[Pentasa (mesalazine) and pregnancy].
We analysed the outcome of 11 pregnancies in women treated for inflammatory bowel disease with mesalazine (Pentasa) during part of or throughout pregnancy. There were 9 healthy babies, one spontaneous abortion (the woman had an uterine malformation) and one infant with multiple malformations (but the mother was not treated with mesalazine during organogenesis). Because of the relatively small number of pregnancies exposed to mesalazine (Pentasa) in this study, these data need to be confirmed by other studies.
Service de Pharmacologie clinique, CHRU Bretonneau, Tours.
A P
AP
Jonville-Bera
C
C
Soyez
A
A
Fignon
C
C
Moraine
C
C
Berger
E
E
Autret
D000328:Adult; D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019804:Mesalamine; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D012189:Retrospective Studies
D000636:Aminosalicylic Acids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine
Pentasa (mésalazine) et grossesse.